{"id":76505,"date":"2026-05-06T23:02:13","date_gmt":"2026-05-06T23:02:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/76505\/"},"modified":"2026-05-06T23:02:13","modified_gmt":"2026-05-06T23:02:13","slug":"novo-nordisk-shares-rise-on-strong-demand-for-glp-1-pill-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/76505\/","title":{"rendered":"Novo Nordisk shares rise on strong demand for GLP-1 pill"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\">Novo Nordisk\u2019s new weight loss pill is proving more popular than expected, boosting the company\u2019s shares as it looks to rebound from a prolonged slump.<\/p>\n<p class=\"yf-1fy9kyt\">The Danish pharmaceutical giant was briefly Europe\u2019s most valuable firm thanks to Ozempic, but has since struggled to keep up with American rival Eli Lilly. Novo said Wednesday that its Wegovy medication saw some <a href=\"https:\/\/www.cnbc.com\/2026\/05\/06\/wegovy-glp1-weight-loss-novo-nordisk-earnings-stock-nvo-ozempic.html\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:1.3 million prescriptions;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;1.3 million prescriptions&quot;}\" class=\"link \">1.3 million prescriptions<\/a> in the first quarter of 2026.<\/p>\n<p class=\"yf-1fy9kyt\">Its CEO said Novo has benefited from the \u201c<a href=\"https:\/\/www.ft.com\/content\/627a884c-8757-42f9-9004-688f6a2c507a?syn-25a6b1a6=1\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:peptide craziness;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;peptide craziness&quot;}\" class=\"link \">peptide craziness<\/a>\u201d in the US, referring to <a href=\"https:\/\/www.newyorker.com\/magazine\/2026\/04\/13\/why-are-people-injecting-themselves-with-peptides\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:the wellness boom;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;the wellness boom&quot;}\" class=\"link \">the wellness boom<\/a> around injectable peptide therapies \u2014 short chains of amino acids increasingly marketed as health hacks. Competition is <a href=\"https:\/\/www.wsj.com\/health\/pharma\/wegovy-maker-novo-nordisk-lifts-guidance-following-strong-launch-of-weight-loss-pill-07d495be\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:set to intensify;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;set to intensify&quot;}\" class=\"link \">set to intensify<\/a> in the second quarter: Lilly last month rolled out its weight-loss pill Foundayo, which isn\u2019t a peptide.<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/91abf02bc0173ddadce7b8c220a49e62.png\" alt=\"Chart showing Novo Nordisk and Eli Lilly stock performance\" loading=\"eager\" height=\"703\" width=\"739\" class=\"yf-lglytj  loaded\"\/> Chart showing Novo Nordisk and Eli Lilly stock performance      <\/p>\n<p class=\"yf-1fy9kyt\">\u2014 <a href=\"https:\/\/www.semafor.com\/author\/jd-capelouto\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:J.D. Capelouto;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;J.D. Capelouto&quot;}\" class=\"link \">J.D. Capelouto<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk\u2019s new weight loss pill is proving more popular than expected, boosting the company\u2019s shares as it&hellip;\n","protected":false},"author":2,"featured_media":76506,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[276,272,33406],"class_list":{"0":"post-76505","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-eli-lilly","9":"tag-novo-nordisk","10":"tag-pharmaceutical-giant"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116530128296709561","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=76505"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76505\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/76506"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=76505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=76505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=76505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}